SABCS 2022 | The real-world RIBANNA study

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, provides an overview of the RIBANNA study, a real-world, noninterventional study conducted in Germany evaluating efficacy, safety, and tolerability of ribociclib plus an aromatase inhibitor/fulvestrant or endocrine monotherapy, or chemotherapy as first-line treatment in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.